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Introduction
This paper presents data from the European Surveillance of Antimicrobial Consumption (ESAC) project on outpatient use of 18 drugs belonging to the macrolide, lincosamide and streptogramin (MLS) group of antibiotics (Table 1) in 2009. As in previous ESAC studies, a classification of macrolides based on their mean plasma elimination half-life, which categorizes them as short-, intermediate-or long-acting, was adopted. 1 The article also reviews temporal trends and seasonal variation in macrolide use.
Methods
The methods for collecting and analysing the data on outpatient use of systemic antibiotics is described elsewhere. 2 Here we provide a detailed description of outpatient MLS use in 2009 in defined daily doses (DDD) per 1000 inhabitants per day (DID) and packages per 1000 inhabitants per day (PID). The number of DDD per package was calculated by dividing DID by PID values for each country. Quarterly outpatient MLS use data in DID were statistically modelled to assess use and seasonal variation of use and their trends from 1997 to 2009 for Europe. Longitudinal data analysis was employed. 3 Through compositional data analysis, annual outpatient use data in DID were modelled to assess trends of the relative proportions of the major MLS subgroups from 1997 to 2009 for Europe. 4 A classification according to their mean plasma elimination half-life, subdividing macrolides into short-acting (half-life ,4 h), intermediateacting (half-life 4 -24 h) and long-acting (half-life .24 h) macrolides (Table 1) , was used to assess the composition of outpatient use in more detail.
Results

Outpatient MLS use in 2009
In terms of the agents listed in Table 1 , seven macrolides each represented .1% of the total MLS use in 2009, with the remainder of the compounds (apart from oleandomycin and troleandomycin, whose use was not reported) each representing ,1% of total macrolide use. Figure 1 shows the total MLS use in 2009, as well as the use of short-, intermediate-and long-acting macrolides, expressed in DID. Total MLS use varied by a factor of 18 between the country with the highest (11.54 DID in Greece) and lowest (0.63 DID in Sweden) use. Variations were even more pronounced when use of short-acting (1.45 DID in the UK versus 0.04 in Austria), intermediate-acting (9. 85 DID in Greece versus 0.07 in Sweden) and long-acting (2.24 DID in Slovakia versus 0.06 DID in Sweden; no use in Latvia) macrolides were compared (Table 2) . While lincosamide (J01FF; mainly clindamycin) use was observed in all countries (ranging from 0.002 DID in Romania to 0.68 DID in Austria), streptogramin use was restricted to the Czech Republic, Germany, Greece, Switzerland, the UK (,0.001 DID) and France (1.04 DID, pristinamycin) (Table S1 , available as Supplementary data at JAC Online).
Erythromycin, a short-acting macrolide, represented .49% of the total MLS use in Norway and the UK, and accounted for .20% of use in Denmark, Iceland, Romania and Sweden. The intermediate-acting macrolides represented the most used subgroup in Austria, Belgium, Bulgaria, Cyprus, the Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia and Switzerland (mainly clarithromycin) and in Denmark and Israel (mainly roxithromycin) (Tables 2  and S1 ). Clarithromycin and roxithromycin use also represented .30% of MLS use in Croatia, Slovenia, Spain and the UK. The longacting macrolides were the most used MLS in Croatia, Iceland, the Russian Federation, Slovenia and Spain (mainly azithromycin) (Tables 2 and S1 ). Azithromycin use represented .20% of total MLS use in another 15 countries. Lincosamides were the most used MLS in Sweden and represented .10% of the total MLS use in Austria, Bulgaria, Finland, Germany, Hungary, Luxembourg, Norway and Poland (mainly clindamycin), while substantial streptogramin use was only observed in France (pristinamycin) ( Table S1 ). Figure 2 shows total outpatient MLS use in 17 European countries for 2009 expressed in PID. In addition, their ranking is depicted according to both DID and PID. Ireland occupied position 3 in DID but position 8 in PID. The DDD per package ranged from 3.1 in Italy to 10.6 in Greece.
Longitudinal data analysis (1997 -2009) For Europe, a significant increase in total outpatient MLS use of 0.02 (SD 0.01) DID per quarter was found, starting from 2.16 Compositional data analysis (1997 -2009) For Europe, the relative use of long-acting macrolides as well as lincosamides significantly increased over time with respect to intermediate-acting macrolides, and their relative use significantly increased with respect to the short-acting macrolides ( Table 3) .
The proportional use of the different macrolide subclasses showed substantial variations, i.e. absolute differences of ≥10% between 1997 and 2009, in more than half of the countries ( Figure S3 , available as Supplementary data at JAC Online). Proportional use of short-acting macrolides decreased by .50% in Iceland, Latvia, Bulgaria and Estonia, by .30% in the Russian Federation, Denmark and Ireland, by .20% in Portugal, Greece and the UK and by .10% in Israel, Spain, Hungary, Norway, Slovenia, Poland, Slovakia, Germany, Italy and the Czech Republic. This decrease was mainly the result of decreasing erythromycin use, except for Italy, the Czech Republic and Slovakia (decreasing spiramycin use) and Bulgaria and Slovenia (decreasing midecamycin use), and was matched by a similar increase in intermediate-and/or long-acting macrolide use in all these countries except for Austria, Finland, Sweden (lincosamides) and France (streptogramins). Overall, intermediate-acting macrolide use increased by .50% in Latvia and Estonia (clarithromycin), by .30% in Croatia and Bulgaria (clarithromycin), by .20% in Lithuania, Ireland, Iceland (clarithromycin) and Denmark (roxithromycin) and by .10% in Greece, Portugal, the Russian Federation, the UK (mainly clarithromycin) and Israel (mainly roxithromycin). It decreased by .10% only in the Netherlands and Spain (mainly clarithromycin).
Long-acting macrolide use (i.e. azithromycin) increased by .30% in Spain, Iceland and the Russian Federation and by .20% in the Netherlands, Poland, Slovakia and Bulgaria. It decreased by .30% in Croatia and by .10% in Lithuania.
Lincosamide use increased by .30% in Sweden (clindamycin) and streptogramin use (pristinamycin) increased by .10% in France. 
Discussion
Levels of MLS use and their extreme (also seasonal) variation among European countries suggest that this subgroup of antibiotics is still prescribed inappropriately in many countries. The seasonal variations in use observed for this subgroup of antibiotics, which are mostly used to treat respiratory tract infections, were more extreme than observed for total use and for penicillin use. 2, 5 This may suggest inappropriate use for conditions such as the common cold, flu and bronchitis. Moreover, variations in macrolide use were more pronounced when assessing the use of short-, intermediate-and long-acting substances. This classification was also used in previous ESAC papers 1 and enabled us to provide the most revealing overview of MLS use in Europe.
In comparison with the 2003 data on MLS use, published in the previous series, 1 midecamycin and telithromycin no longer represented .1% of the total MLS use. For telithromycin, introduced in 2001, a strong increase up to 2005 was followed by a marked decline, which coincided with European Medicines Agency warnings on the safety of telithromycin published in 2006 and 2007. 6, 7 MLS use increased in 10 countries during 1997-2009, most remarkably in Greece (by .7 DID), and in 2009 Greece remained the highest consumer of MLS in DID in Europe. When using PID as the outcome measure instead of DID, we observed no important shifts in ranking except for Ireland (Figure 2 ). For MLS, there was less variation in DDD per package in each country (average 6.5 DDD per package) compared with penicillins. 5 Among MLS, macrolides were the most used subgroup (except for Sweden, where lincosamide use predominated), and among the macrolides the intermediate-acting subgroup (mainly clarithromycin) was predominantly used in the majority of the European countries. Only in the UK and Norway did the use of short-acting macrolides (i.e. erythromycin) remain predominant. The lower price of short-acting macrolides could be a possible explanation for their predominant use in the UK, as the NHS provides a financial incentive to prescribe cheaper medicinal products. 8 Reimbursement can be a very powerful tool to control antibiotic use by general practitioners, 9 but a more detailed assessment of the different national reimbursement systems is needed to fully understand their influence on shifts (or lack of shifts) in the choice of antibiotic subgroup or substance. Irrespective of the most used subgroup, a shift in prescribing trends from the older to newer analogues, which has also been recorded for other antibiotic subgroups, Outpatient macrolide, lincosamide and streptogramin use in Europe (ESAC) vi43 JAC recurrent tonsillitis/pharyngotonsillitis within 14 days or as an alternative for penicillin V in case of penicillin allergy in acute tonsillitis/pharyngotonsillitis, skin and soft tissue infection and community-acquired pneumonia in adults. 10 Data linking prescriptions with indications could be helpful in reaching a better understanding of such trends in use.
Overall, there was an increase in the proportional use of the intermediate-acting (mainly clarithromycin) and/or long-acting (mainly azithromycin) subgroups at the expense of the shortacting subgroup (mainly erythromycin) during the 13 years of observation. In Spain, the Russian Federation and Iceland the long-acting macrolides (i.e. azithromycin) became the predominant group. Decreasing use of the short-acting macrolides, like erythromycin, which are inferior to the newer analogues clarithromycin and azithromycin in terms of pharmacokinetic profiles and adverse drug reactions, could be considered a positive trend. However, both clarithromycin and azithromycin have been shown to cause enhanced resistance selection in oral streptococci. 11 The currently reported ESAC data should contribute to a better understanding of the link between macrolide use and resistance. Although the current MLS classification might not be ideal, it nevertheless provides us with a tool to describe macrolide use in Europe in a more comprehensive manner than before and to assess the future impact of guidelines and interventions in promoting better use of these drugs. 
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